Baxalta pursues cellular therapy | Chemical & Engineering News
Volume 94 Issue 10 | p. 17 | Concentrates
Issue Date: March 7, 2016

Baxalta pursues cellular therapy

Department: Business
Keywords: oncology, pharmaceuticals, cancer immunotherapy, CARTs

Baxalta will pay $105 million to genome-editing firm Precision BioSciences as part of a pact to develop off-the-shelf chimeric antigen receptor T-cell (CART) therapies for six cancer targets. The most advanced CART therapies have been highly personalized: Companies reengineer a patient’s own T cells to find and destroy cancer cells. Precision BioSciences’ genome-editing technology allows CARTs to be developed from healthy donors as treatments for multiple patients. The partners expect the first allogeneic CART therapy will enter the clinic late next year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment